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ABSTRACT
Objectives: This pilot study aimed to evaluate the feasibility and potential benefits of a novel 
biofeedback breathing training for achieving sustained increases in pCO2 levels.
Methods:  Twelve asthma patients were randomly assigned to an immediate 4-week treatment 
group or waiting list control. Patients were instructed to modify their respiration in order to 
change levels of end-tidal pCO2 using a hand-held capnometer. Treatment outcome was 
assessed in frequency and distress of symptoms, asthma control, lung function, and variability 
of peak expiratory flow (PEF). 
Results: We found stable increases in pCO2 and reductions in respiration rate during treatment 
and 2-month follow-up. Mean pCO2 levels rose from a hypocapnic to a normocapnic range at 
follow-up. Frequency and distress of symptoms was reduced and reported asthma control 
increased. In addition, mean PEF variability decreased significantly in the treatment group. 
Conclusions: Our pilot intervention provided evidence for the feasibility of pCO2-biofeedback 
training in asthma patients. 
Keywords: Asthma; hypocapnia; breathing training; pCO2; biofeedback
                                                                                              PCO2 Biofeedback in Asthma  3
Abbreviations:
pCO2: maximum partial pressure of CO2
fR: respiration rate per minute
FEV1: forced expiratory volume in the first second
FVC: forced vital capacity
Rint: interrupter resistance
PEF: peak expiratory flow
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Alternative and complementary interventions for asthma have attracted considerable 
attention in recent years (Wright, 2004). Among these, interventions targeting breathing 
behavior have been recommended as adjunctive treatments for some time. However, little 
empirical evidence is currently available in support of the efficacy of various forms of 
breathing training (Ernst, 2000; Holloway & Ram, 2004; Ritz & Roth, 2003). This is 
surprising because a number of these methods, such as nasal breathing, pursed-lip breathing, 
hypoventilation, or respiratory muscle relaxation, are based on valid psychophysiological 
rationales (Ritz & Roth, 2003). One recent trial of breathing training teaching slow, regular 
and abdominal breathing to reduce potential hyperventilation showed positive effects on 
patients’ quality of life (Thomas, McKinley, Freeman, et al., 2003). However, no 
physiological measurements were reported that would have confirmed successful 
manipulation of breathing patterns or treatment effects on lung function. Another breathing 
training method that promotes a reduction in hypocapnia directly by slow and shallow 
breathing and breath-hold exercises has generated more systematic research in controlled 
intervention studies. Originally developed by the Russian physician Buteyko (Stalmatski, 
1997), the technique is based on the idea that asthma exacerbations are caused by chronic 
hypocapnic breathing, and that retraining of patients’ breathing pattern to achieve a long-term 
reduction in ventilation will result in an improvement in asthma control. Recent controlled 
trials of this technique reported reductions in medication (in particular -adrenergic 
bronchodilators) and improvements in quality of life of the patients (Browler, Green, 
Mitchell, 1998; Cooper, Oborne, Newton, et al., 2003; Opat, Cohen, Bailey, et al., 2000; 
McHugh, Aitcheson, Duncan, et al., 2003).
 It has been known for some time that hypocapnic hyperventilation exacerbates asthma 
(Herxheimer, 1946). Experimental studies have demonstrated a decline in lung function when 
carbon dioxide partial pressure (pCO2) is reduced (Newhouse, Becklake, Macklem, et al., 
1964; van den Elshout, van Herwaarden, & Folgering, 1991; Sterling, 1968). Also, lower 
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pCO2 levels have been linked to airway hyperresponsiveness in asymptomatic asthma patients 
(Osborne, O’Connor, Lewis, et al., 2000). Excessive ventilation without hypocapnia is a key 
mechanism in the development of bronchospasm in asthma and has been suggested to explain 
exercise-induced bronchoconstriction (McFadden & Gilbert, 1994). Repeated excessive 
ventilation with cold dry air has also been shown to result in increases in airway 
hyperresponsiveness, inflammation and in impairments in response to ß-adrenergic 
bronchodilators in an animal model (Davis & Freed, 2001; Davis, Schofield, & Freed, 2003).  
There is evidence for basal ventilatory states or ventilatory responses that put asthma patients 
at greater risk of exacerbations. While oxygen saturation is usaully normal in asthma patients 
except for periods of severe exacerbation (Wagner, Hedenstierna, & Rodriguez-Roisin, 
1996)), studies have found lower resting pCO2 in patients than in healthy controls (Hombrey 
et al., 1988; Osborne, O’Connor, Lewis, et al. 2000; Ritz, Wilhelm, Meuret, & Roth, 2003) or 
stronger minute ventilation or respiratory drive at baseline or in response to exercise (Ritz, 
Dahme, Wagner, 1998; Varray, Prefaut, 1992), added resistive loads (Kelsen, Fleegler, & 
Altose, 1979), or methacholine-induced bronchoconstriction (Fujimori et al., 1996). 
Hypocapnia has also frequently been observed in asthma attacks (McFadden & Lyons, 1968).
While there is some evidence in support of the basic assumptions of the Buteyko 
breathing technique as an adjunctive treatment for asthma, published controlled trial have 
provided little evidence that pCO2 had been targeted successfully (Ritz & Roth, 2003; Bruton 
& Holgate, 2005; Walters & Johns, 2001). None of the reported trials has shown that 
respiratory gas exchange can be significantly altered by this type of breathing training. Only 
one included measurements of pCO2 and minute ventilation, but significant changes at 4 
weeks post-training or 2-months follow-up were only seen in the latter index (Cooper, 
Oborne, Newton, et al. 2003). Demonstrating that stable pCO2 levels have been brought into a 
healthy range is necessary to confirm Buteyko’s idea of how his hypoventilation training 
works (Stalmatski, 1997). Without that, only nonspecific factors may be responsible for the 
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reported improvements.  For example, any therapeutic rationale that strongly emphasizes a 
reduction in bronchodilator use might well cause patients to report reduction of that use after 
weeks of training. 
Hence, we designed an adjunctive training for asthma patients that directly targets 
pCO2 and tested it in a small number of patients. The results would encourage or discourage a 
more comprehensive clinical intervention trial using hypoventilation training. Feedback of 
pCO2-levels can bring them under the voluntary control of the patient, as has been 
demonstrated with patients suffering from chronic hyperventilation (Folgering, Lenders, & 
Rosier, 1980; van Doorn, Folgering, & Colla, 1982). In prior research, we successfully 
developed and tested a capnography-assisted breathing training for reducing hypocapnia in 
patients with panic disorder (Meuret, Wilhelm, & Roth, 2001, 2004). The technique resulted 
in elevations of end-tidal pCO2-levels during laboratory testing over weeks and months. In 
this study we report the adaptation and pilot testing of this technique in asthma patients. Our 
main goal was to demonstrate the feasibility of the technique and to provide initial evidence 
of its efficacy.
METHODS
Participants
Adult asthma patients were recruited by advertisement in local newspapers, online message 
boards, and posters in medical school departments for a study of breathing training in 
asthma. The assessment schedule included participation in an initial interview on psychiatric 
and asthma history, in two laboratory assessments, one 24-hour ambulatory monitoring day, 
and a 4-week breathing training program with an 8-week follow-up assessment. Potential 
participants had to be non-smokers between 18 and 60 years old, which reduced the risk of 
including patients with chronic obstructive pulmonary disease. Further exclusion criteria 
were use of oral corticosteroids in the previous 3 months, cardiovascular disease,
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neurological disorders, clinically significant levels of depression, or life-time diagnosis of 
schizophrenia, dementia, or psychosis. Patients were also screened for the presence of 
anxiety disorder, which was not an exclusion criterion, but would potentially add to the 
interpretation of findings. Twenty-one patients were screened initially, of which 9 (42.9%) 
had scheduling problems or were not eligible because they did not meet the inclusion 
criterion. The final 12 patients were randomly assigned to an immediate 4-week treatment 
group (n=8) or a 4-week waiting list group (n=4). Waiting list patients were offered an 
identical treatment after the four weeks. 
Suitable candidates were invited for medical history taking, which focussed on their 
asthma, and included lung function testing by spirometry. Patients also filled in a structured 
questionnaire on various aspects of their disease manifestation and on diagnostic procedures 
(lung function testing, bronchial provocation tests, allergy tests), for which they had to contact 
their general practitioner or specialist and ask for documentation. All patients had a present 
diagnosis of asthma. Only one waiting-list patients reported brief previous contact with 
training in breathing techniques. Participation was voluntary, and informed consent was 
obtained from all patients. The study was approved by ethical review committees of the VA 
Palo Alto Health Care System and Stanford University Medical School.
Instruments and measures
End-tidal pCO2 was measured with a light (320g), handheld (65 x 128 x 35 mm), battery-
operated capnometry device (Capnocount mini, Weinmann, Germany), which analyzes 
exhaled breath pumped into the device through a nasal cannula (Wilhelm, Alpers, Meuret, et 
al. 2001). The instrument displays breath-by-breath end-tidal pCO2 (in mmHg) and 
respiration rate (fR) (in breaths/min), and records them with the time and date of the 
measurement. 
Mechanical lung function was measured with an electronic pocket spirometer 
(Jaeger/Toennies, AM2). The best of three expirations was stored in the electronic memory 
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of the device together with a volume-time profile that allows for detection of submaximal 
performance of the maneuver. Forced expiratory volume in the first second (FEV1) was 
used as the primary outcome measure. In addition, peak expiratory flow (PEF) and FEV1 
divided by forced vital capacity (FVC) were extracted at the first session. Before 
spirometry, interrupter resistance (Rint; MicroRint, MicroMedical Ltd., UK) was measured 
and Rint was determined as the average of the median of 10 inspiratory and 10 expiratory 
interruptions. These measurements were taken initially at each of the five training sessions 
by an investigator who did not conduct the sessions. This measure of respiratory resistance 
has the advantage of being effort-independent and provides a more direct index of airway 
constriction (Ritz et al., 2002). Before and after the 4-week treatment and at follow-up, 
patients recorded their PEF five times daily: in the morning after awakening (before
bronchodilator), and at approximately 11am, 2 pm, 5 pm, and 8 pm. A brief tone sequence 
from the AM2 at those times reminded patients to perform the PEF test. From the 3-day 
recordings, % PEF variability was extracted as follows (Reddel, Jenkins, & Woolcock, 
1999): the morning value before bronchodilator use divided by the patient’s personal best 
value during the 3-day period, multiplied by 100, and subtracted from 100. While peak flow 
diaries have been shown to be prone to substantial problems with missing values (e.g., 
Chowienczyk et al., 1994), adherence of patients with this brief protocol was excellent, with 
the average number of measurements per day being 5.5 (range: 3.7-6.7) at pre-training, 5.3 
(4.3-5.7) at post-training, and 4.9 (3.3-5.7) at follow-up (patients often performed additional 
measures beyond the specified times). Compliance did not change significantly thoughout 
the observation period, Friedman-Test (2)=1.3, p=.527.    
Questionnaire measures. Initially, patients filled out a set of questionnaires at home, which 
covered demographics and information on asthma history, symptom patterns, recent health 
care utilization, medication use, and effect of medication. Patients were asked to rate how 
effective their current medication was (rating 1-4, “always”, “most of the times”, 
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“sometimes”, or “never”). At the beginning of each therapy session they filled out a 
questionnaire on frequency of asthma symptoms and how much distress they had caused 
(“symptom bother scale”) (Steen, Hutchinson, McColl, et al., 1994), and self-report items of 
the Asthma Control Questionnaire (Juniper, O’Byrne, Guyatt, et al., 1999) for the period of 
the previous week. At the 1st and 5th session and at follow-up the Health Survey Short Form-
12 (Ware, Kosinski, & Keller, 1996) was also administered. Patients undergoing training 
also filled in the Positive Affect Negative Affect Schedule (PANAS; Watson, Clark & 
Tellegen, 1988), from which we analyzed the negative affect subscale scale to explore 
whether the training had a nonspecific effect on patients’ negative mood.   
After follow-up assessments, patients were given a treatment evaluation sheet, which 
they were asked to complete at home and to return in a stamped envelope. On the sheet were 
the following questions (rated from 0 – 10, “not at all” to “extremely”): “How logical does 
this treatment appear to you for helping people with asthma?”, “How confident are you that 
this treatment will improve your symptoms of asthma?”, “How confident are you that this 
treatment will improve the control you have over your asthma?”, “How confident would you 
be to recommend this treatment to a friend with asthma?” “How successful do you think this 
treatment would be in dealing with other problems, for example, headaches or 
sleeplessness?”
Treatment procedures
General rationale and goal of the training. Our breathing training was offered only as an 
adjunctive treatment. Patients were advised to continue their regular preventative medication 
as recommended by their physician at a stable level throughout the 4 weeks of treatment. A 
clinical psychologist experienced in breathing techniques conducted the treatment sessions on 
an individual basis. The breathing training rationale cited evidence that hypocapnia and 
excessive ventilation adversely affect lung function in asthma and can be involved in asthma 
exacerbations. The training was aimed towards voluntarily increasing self-monitored end-tidal 
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pCO2 by reducing fR and variability in the respiratory pattern (e.g. intermittent deep breaths, 
sighing) through breathing exercises. It was adapted from a breathing retraining protocol 
recently developed for panic patients (Meuret, Wilhelm, & Roth, 2001; 2004).  
Before treatment, patients underwent a 24-hour ambulatory monitoring of autonomic 
function (electrocardiogram, electrodermal activity, skin temperature), lung function 
(spirometry) and respiration (inductance plethysmography, capnography). Recordings of 
respiration were subsequently used qualitatively in the initial session of the breathing training. 
Components of the treatment. The training consisted of five weekly treatment sessions (initial 
session plus four treatment sessions) of approximately 1 hour duration. The treatment had five 
major components: (a) educating patients about the role of breathing in asthma exacerbations, 
(b) directing their attention to their respiratory patterns, particularly those observed in 24-hour 
monitoring records, (c) having them perform various breathing maneuvers with capnometer 
feedback to experience how changes in breathing affect physiology and symptoms, (d) 
teaching them ways to simultaneously control pCO2 levels, fR, and tidal volume, (e) and 
having them practice breathing exercises at home. 
Home exercises. An individual home training exercise consisted of three parts: (a) an initial 2-
min period, during which patients sat quietly with their eyes closed (b) a 10-min paced 
breathing period during which patients breathed in synchrony with tones from a tape while 
trying to increase pCO2 and decrease fR using the display of the capnometer for feedback, and 
(c) a 5-min breathing period without pacing tones during which patients were to maintain their 
previously paced fR and pCO2 level using feedback from the display. Pacing tones started at 13 
breaths/min in the first week, and switched to 11, 9, and 6 breaths/min in subsequent weeks. 
Before and after each exercise patients rated their current symptoms and mood in the electronic 
diary of the pocket spirometer and then measured their lung function. They also filled in a 
separate diary sheet with information on medication, prior physical activity, and their observed 
pCO2 levels, fR, and PEF. All instructions and pacing tones for home exercises were given on 
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standardized pre-recorded audiotapes, and patients were provided with a pocket-sized cassette 
player. Patients were instructed to gradually adjust their breathing patterns (fR, rhythm, and 
depth) though slow, shallow, and abdominal breathing to reach or maintain a pCO2 level 
around 40 mmHg. If levels exceeded 45 mmHg, they should reduce their efforts and let levels 
fall back closer to 40. 
Treatment sessions. In the first two weeks the emphasis was largely on stabilization of 
breathing patterns (fR and rhythm), while in the last two weeks it was shifted to normalizing 
pCO2. For patients with initial pCO2 levels within the normal range (37 - 40 mmHg; 3 patients 
in the treatment group, 2 in the waiting list), treatment focused on regularity of breathing to 
prevent pCO2 fluctuations. Exercises were to be performed twice a day for 17 min, at home or 
elsewhere. 
In the first session patients were presented a series of charts with information about effects 
of hyperventilation on lung function and symptoms in asthma, the relationship between 
symptoms, anxiety, and hyperventilation, and the therapy goals. The weekly hourly sessions 
began with filling out weekly questionnaires on symptoms and asthma control, followed by 3-
min pCO2 measurements and lung function assessments. Capnometer exercise data recorded 
during the previous week were then reviewed. The trainer examined individual capnometer 
print-outs with the patient, looking for evidence of concordance between changes in pCO2 and 
fR and changes in symptoms before and after the exercises. Analysis of exercises was 
followed by further training with the feedback device. At the end of the session, patients were 
instructed on how to use the new breathing tapes. The final session concentrated on 
maintenance of treatment gains. 
Patients returned to individual treatment and assessment sessions at the same time of the 
day ± 2 hour. Those who used higher doses of bronchodilator medication were encouraged to 
reduce those doses and practice the breathing maneuvers as long as symptoms were still 
tolerable. At the 5th treatment session, the pacing tapes and capnometer were collected from 
                                                                                              PCO2 Biofeedback in Asthma  12
the patients, who were encouraged to continue applying the breathing techniques whenever 
they found them helpful. 
Waiting list condition. Waiting-list patients were asked to start treatment after a period of 4 
weeks. They received the same assessment of PEF variability, basal pCO2, lung function, 
asthma symptoms, and health status as the immediate treatment patients. Following the 
waiting-list period, two patients chose to participate in the training, while two others had 
either scheduling problems or an asthma exacerbation requiring oral corticosteroids.
Data analysis
Because the size of the control group was small, we limited inferential statistics to the 
treatment group and used control group means for qualitative comparison only. Treatment 
effects were analyzed with one-way repeated measures ANOVAs with pre-treatment, post-
treatment, and follow-up as three time points. Where the sphericity assumption was violated, 
significance levels were corrected using the Geisser-Greenhouse epsilon. In those cases, we 
report the original degrees of freedom and the corrected significance levels. Bronchodilator 
use (item 6 of the asthma control questionnaire) was analyzed using the nonparametric 
Freedman rank test due to a lack of normal distribution. Post-hoc comparison of post-
treatment and follow-up with pre-treatment means used the Newman-Keuls procedure. 
RESULTS
Patient characteristics
Patients in the treatment group were predominantly married women, Caucasian (beyond that, 
1 woman reported being 80% African American, 20% Native American, and 1 woman 100% 
Asian/Pacific Islander), currently employed, and well educated (on average 17 years) (Table 
1). Five treatment patients (62.5%) reported onset of asthma before the age 18 years. Control 
patients were mostly comparable, but were younger and 2 (50%) were Non-Caucasian (1 
woman 50% Spanish 50% Tunesian, 1 man 100% Hispanic). Patients had mainly mild 
intermittent to moderate persistent disease severity; with 50% treatment and 25% control patients 
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reporting daily symptoms. Daily activities were affected every day in 2 (25%) treatment and 1 
(25%) control patient. Nighttime symptoms at least up to 2 times per month were reported by 6 
(75%) treatment and 2 (50%) control participants. All patients reported that their medication 
helped against shortness of breath “most of the time”, while 1 treatment (12.5%) and 1 control 
patient (25%) reported that it helped against cough and wheezing only “sometimes” or “never”.  
Patients reported only up to one emergency treatment in the previous year, with proportionally 
more controls patients reporting such incidences (see Table 1). Also, FEV1/FVC was somewhat 
lower in the control group. The beginning of treatment was distributed across one year (one 
patient in January, one in March, two in April, one in May, one in August, one in September, and 
one in November), while two waiting-list patients were enrolled in May, and two in October. 
Most patients except for one in the treatment and one in waiting-list group reported having 
asthma symptoms typically in more than one season. One patient reported having had panic 
attacks in the past, but did not have any attacks during treatment or follow-up.
 Treatment outcome
Evidence of manipulation success: End-tidal pCO2 and respiration rate. The treatment 
resulted in significant pCO2 increases and fR decreases that were stable through follow-up, as 
shown by mean values recorded at the beginning of the first and last treatment and follow-up 
session (Table 2). Data from individual patients showed pCO2 values at follow-up that were 
higher than at pre-treatment in all participants of the treatment group, and respiration rate 
dropped substantially in five participants (Figure 1). Waiting-list patients remained mostly 
stable. One participant had rather high pCO2-levels (50 mmHg) at post-treatment 
measurements, but showed more moderate levels (42.7 mmHg) at follow-up. Also, inspection 
of his records during the 4th training week showed that the maximum pCO2 values he had 
reached during individual exercises ranged from 40 to 44 mmHg. 
Treatment adherence. None of the recruited patients ended their participation in the trial 
prematurely. Of the required 13 weekly home exercises, patients completed 11.3 ± 2.7, 13.0 ± 
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1.1, 12.6 ± 1.8, 11.3 ± 4.1 home exercises, for the 1st, 2nd, 3rd, and 4th week, respectively. 
Some patients performed one additional exercise and one of them 3 additional exercises in 
one week. Only one patient showed a low compliance during the 4th week of the training with 
a total of 3 home exercises. 
Questionnaire measures. Significant decreases in frequency of symptoms and distress by 
symptoms were reported in the treatment group (Table 2). At the same time, self-reported 
asthma control increased. General health status measured by the SF-12 and negative affects 
measured by the PANAS remained unchanged. 
Lung function. Basal lung function with regard to FEV1 and Rint remained stable. On the other 
hand, PEF variability fell through follow-up. Individual values suggested a rather uniform 
decrease in symptoms and PEF variability for treatment patients (Figure 2).
Medication. All patients except for one in the treatment group remained on a stable level of 
preventative medication during the four weeks of treatment. This patient increased his inhaled 
corticosteroid dose in the 4th week due to a cold. He then discontinued all medication for the 8 
weeks leading up to follow-up assessments, and reported being able to control symptoms 
(which were mainly cough) usually within one minute using breathing techniques. 
Recalculating the analyses without this patient did not change findings substantially. At 
follow-up one more patient had discontinued all medication, and one had reduced the inhaler 
corticosteroid dose, while one patient had been prescribed additional leukotriene inhibitor 
medication, and for one, the leukotriene inhibitor had been replaced by an inhaled 
corticosteroid. Preventative medication levels remained stable in waiting-list patients.
On average, bronchodilator use remained unchanged, at rather low levels. Initially, 
only four patients in the treatment group reported bronchodilator use, and none in the control 
group. After four weeks, three treatment patients had increased their use or started use, while 
three had decreased their use. Two patients in the control group had started to use their 
bronchodilators after the 4 weeks on waiting list. At follow-up, four treatment patients had 
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decreased, and one increased their use. One patient reported having had a cold-induced 
exacerbation a few weeks before the follow-up assessments, which had required an increase 
in bronchodilator doses. She reported no benefits of breathing exercises for these symptoms, 
but thought that the exercises had speeded up recovery from her asthma exacerbation.  
Patients’ treatment evaluation
Five patients in the treatment group returned their evaluation sheets. Most of them 
found the treatment rationale logical (ratings >= 7; mean = 7.2, range 5 - 9); only one patient 
found it “somewhat logical”. On average, patients were confident that it would enable them to 
control their symptoms (mean = 6.6, range 2-10) and control their asthma (mean = 6.0, range 
2-10). They were likely to recommend the training to a friend (mean = 7.2, range 5-10), and 
thought it may be helpful for other diseases as well (mean = 6.8, range 5-9). The two control 
patients participating in the training after the waiting period also returned their forms and 
showed evaluations closely matching these, with ratings between 5 and 10 on individual 
scales.
DISCUSSION
In this pilot-study we tested a new breathing training with capnometer feedback to 
increase asthma patients’ pCO2 levels. We found stable increase in pCO2 across an 8-week 
follow-up period in patients trained with this method. Prior studies attempting to train 
hypoventilation did not attempt to measure changes in this key parameter or were not able to 
demonstrate substantial changes (Browler, Green, & Mitchell, 1998; Cooper, Oborne, Newton, 
et al., 2003; Opat, Cohen, Bailey, et al., 2000; McHugh, Aitcheson, Duncan, et al., 2003). 
Compared to other methods our training had the advantage of allowing for an immediate 
manipulation check by the patient and a systematic evaluation of pCO2-changes by the therapist. 
The feedback of a key physiological parameter increases the plausibility of the training and 
rewards the patient for successful breathing change. Electronic storage of the data allows a 
review of exercises and serves as an important element in increasing patients’ compliance with 
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the home training schedule. Using an electronic spirometer with diary function, our home 
training relied strongly on electronic recording techniques, which have become state-of-the art in 
ambulatory and self-management studies with asthma patients (Chowienczyk, Parkin, Lawson, 
et al., 1994; Milgrom, Wamboldt, & Bender, 2002; Ritz & Steptoe, 2000). Future evaluations of 
this training could be enhanced by additional electronic monitoring of medication usage (Berg, 
Dunbar-Jacob, & Rohay, 1998).
These initial results also suggest benefits of the training on patients’ asthma control. 
Frequency and distress of symptoms was reduced, and asthma control increased, over the weeks 
leading up to follow-up assessments. Lung function remained stable, although decreases were 
seen in respiratory resistance that might have been significant with a larger sample size. A 
greater sensitivity of these more direct measures of airway obstruction to the effects psychosocial 
interventions has been observed before (Lehrer, Vaschillo, Vaschillo, et al., 2004; Ritz, Dahme, 
DuBois, et al., 2002). 
We also observed a substantial decrease in variability of lung function across weeks to 
below values typically used as criteria of asthma diagnosis (NHLBI, 2003). Thus, improvement 
through training extended beyond patients’ perception of their disease to a somatic outcome 
measure central to the pathophysiology of asthma. Although the relationship between PEF 
variability and airway hyperresponsiveness has been debated (Douma, Kerstjens, Roos, et al., 
2000; Reddel, Salome, Peat, et al., 1995), such findings are compatible with prior findings of a 
negative correlation between pCO2 and hyperresponsiveness to methacholine challenge 
(Osborne et al., 2000). It is likely that additional benefits of an adjunctive breathing training will 
be less apparent in basal lung function (or only be visible in more direct measures of airway 
obstruction) than in a reduction of fluctuations in symptoms. At follow-up, in addition to 
reduction in symptoms and greater asthma control through questionnaires, two patients also 
reported that they felt improvements in their ability to control symptoms and to recover from 
asthma exacerbation. Although spirometric indices of lung function are typically dependent on
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patients’ effort (Ritz et al., 2002), we do not think that the observed reductions in PEF variability 
could easily be explained by this factor. Complicated and less plausible assumptions would have 
to be invoked to explain this finding, such as a reduction in the inconsistency in patients’ effort 
due to therapy. Given the particular index we chose for PEF variability, which contrasts lowest 
morning values with the maximum value during the measurement period (Reddel et al., 1999), 
this assumed reduction in inconsistency, would also have to be specific to certain times of the 
day.     
Because our sample was not selected for high levels of severity or low asthma control, 
we may have been less able to show substantial changes in some of the outcome variables. On 
average, initial lung function was close to 100% of predicted, and bronchodilator medication use 
was low. Studies of the Buteyko technique have especially demonstrated reductions at high 
levels of bronchodilator use.  Reductions are important, but assessment by self-report has 
limitations (Berg, Dunbar-Jacob, & Rohay, 1998). It is not surprising that an intervention that 
stresses reduction in reliever medication as an important goal leads patients to report such 
reductions at the end of the training, at least in part because patients have some decision latitude 
in the level of usage of this medication for symptoms. Future trials may profit from inclusion of 
more severe cases of asthma or patients with overuse of bronchodilator medication.
The range of applicability of hypoventilation training for asthma patients remains to be 
determined. Although excessive minute ventilation and low pCO2 are often reported in asthma 
(Osborne, O’Connor, Lewis, et al. 2000; Ritz, Dahme, & Wagner, 1998; Varray & Prefaut, 
1992, Kelsen, Fleegler, & Altose, 1979), a sizable number of patients show normal or close to 
normal levels of pCO2. The target for such patients can be stabilization of normal levels of pCO2
by more regular breathing. However, little is known about the importance of variability of 
breathing patterns in daily life for asthma symptoms. Highly variable breathing patterns with 
intermittent deep breaths (sighs) are often observed in panic patients (Abelson, Weg, & Nesse, 
2001; Wilhelm, Gerlach, & Roth, 2001) and could lead to maintenance of low pCO2 levels. 
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Intermittent deep inspirations dilate the airways and decrease hyperresponsiveness of the 
airways, but may also lead to bronchoconstriction in more severe asthma (Fish, Ankin, Kelly, et 
al., 1981; Lutchen, Jensen, Atileh, et al., 2001). In our study, three patients with high initial pCO2
levels showed only small increases from pre-treatment (39.0 ± 1.1 mmHg) to post-treatment 
(39.6 ± 3.1 mmHg) and follow-up (41.6 ± 1.9 mmHg), and further qualitative inspection of their 
means in outcome variables suggested lower initial symptom scores (1.1 ± 0.3 vs. 1.5 ± 0.6) and 
PEF variability (13.2 ± 6.7 vs. 32.9 ± 14.5 %), combined with smaller reductions across training 
than in the 5 patients starting with lower pCO2 levels (31.7 ± 2.4 mmHg). Although patients 
were relatively positive in their final evaluation of the training, measurable benefits of the 
training in terms of asthma control may be restricted to patients in the hypocapnic range.
Our breathing training was originally developed to correct hypocapnic breathing 
patterns in patients with panic disorder (Meuret, Wilhelm, & Roth, 2001). In a recent clinical 
trial we demonstrated substantial reductions in panic symptomatology over a 1-year period 
(Meuret, Wilhelm, Ritz, et al., under review) in these patients. Asthma patients are more 
likely than the general population to also suffer from panic disorder (Carr, 1998; Hasler, 
Gergen, & Kleinbaum, 2005; Ritz, Thoens, Fahrenkrug, et al., 2005), and emotion-induced 
overbreathing has been observed in asthma patients (Clarke & Gibson, 1980), particularly in 
anxious states surrounding asthma attacks. Panic-fear has been linked to suboptimal 
management of asthma, such as greater use oral corticosteroid (Hyland, Kenyon, Taylor, et 
al., 1993; Kinsman, Spector, Shucard, et al., 1974; Ritz, Bobb, Edwards, et al., 2001). Thus, 
an additional benefit of the training could lie in teaching of skills to reduce comorbid panic, 
particularly the risk of panic-induced overbreathing in the event of severe asthma symptoms. 
Our current findings do not allow disentangling effects of slow breathing training from 
effects of systematic biofeedback-induced increases in pCO2. Slow breathing training has 
been shown to be beneficial in cardiovascular disease (Bernardi, Spadacini, Bellwon, et al., 
1998; Schein, Gavish, Herz, et al., 2001), probably due to its potential to increase baroreflex 
                                                                                              PCO2 Biofeedback in Asthma  19
sensitivity (Bernardi, Porta, Spicuzza, et al., 2002; Joseph, Porta, Casucci, et al., 2005).  
However, little is know about changes in breathing pattern or slow breathing alone in asthma 
(Ritz & Roth, 2003). Recent research combining slow breathing with heart rate variability 
biofeedback has demonstrated beneficial effects on lung function and steroid medication 
needs in asthma (Lehrer, Vaschillo, Vaschillo, et al., 2004), as well as symptomatic and 
functional improvements in chronic obstructive pulmonary disease (Giardino, Chan, Borson, 
et al., 2004), but mechanisms behind such effects are largely unexplored. Although 
improvements in oxygen saturation have been observed for typical breathing frequencies (6-8 
breaths/min) employed by such studies (see also Bernardi et al., 1998), these effects cannot 
easily explain changes in mechanical lung function, such as in basal respiratory resistance 
(Lehrer et al., 2004), or PEF variability, as observed in the present study. Future studies need 
to address the relative importance of various breathing maneuvers in respiration-oriented 
interventions and pathways through which they can affect organic disease manifestations. 
Our study was clearly limited in its sample size and its lack of a control group large 
enough for meaningful inferential statistics. However, our main goal was to pilot-test the 
feasibility and benefits of this newly developed training. The substantial increases we observed 
in pCO2 across training are difficult to attribute to nonspecific factors such as attention or mere 
temporal fluctuations. Although qualitative comparison with the control group suggested 
superiority of the intervention, nonspecific factors may have contributed to the improvements. 
Greater awareness of the disease and our requirements to continue regular medication may have 
resulted in an improved asthma self-management. In addition, expectancy of improvement 
generated by the treatment rationale may have impacted on self-report of symptoms and asthma 
control, but improvement in PEF variability would be difficult to explain by such effects. Also, 
the lack of changes in negative affect throughout the observation period argue against 
nonspecific effects through anxiety reduction, which might be invoked as an explanation derived 
from the original application of the pCO2 biofeedback training to panic patients (Meuret et al., 
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under review).  Future studies will have to implement comparison interventions that follow 
monitoring protocols controlling closely for the amount of self-attention, attention directed to the 
patient by the therapist, and expectancy of improvement by the patient.
CONCLUSION
Our pilot intervention has provided initial evidence for the feasibility of 4-week pCO2-
biofeedback training in asthma patients. Stable increases in pCO2 can be achieved by a 
combination of five expert-guided sessions and daily home exercises using slow paced 
breathing and feedback of actual pCO2-levels. The training allows for a more direct test of the 
assumptions underlying breathing interventions such as the Buteyko technique, because it 
targets directly the basic physiological parameter of the pathophysiological rationale of the 
technique. The training was well tolerated by our patients and reduced symptoms and 
variability of PEF. We therefore recommend a more thorough investigation of its benefits as 
an adjunctive behavioral self-management technique for asthma patients.
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Table 1. Demographics and asthma-related variables among patients in immediate treatment and 
waiting list conditions
Treatment 
(n=8)
Wait-list control
(n=4)
Patient characteristics
Gender, women (%) 
Age in years (mean, range)
Ethnicity, White Caucasian (%)
75.0
43.5 ± 11.0
75.0
75.0
34.0 ± 15.5
50.0
Family and educational background
Married (%)
Years of education
Currently working (%)
87.5
17.0 ± 1.9
75.0
50.0
17.3 ± 2.5
75.0
Asthma characteristics
    Age of asthma onset, years, (mean ± SD)
    Family history of asthma and/or allergies positive, (%)
    Skin test for allergy, positive (%)
    Frequency of symptoms, rating 1-4, (mean ± SD)
    Limitation of daily activities, rating 1-4, (mean ± SD) 
    Night time symptoms, rating 0-4, (mean ± SD)
Asthma care
        Short-acting bronchodilators (%)
        Long-acting bronchodilators (%)
        Inhaled corticosteroids (%)
        Leucotriene inhibitors (%)
       Anti-histaminics (%)
       Mast cell stabilizers (%)
       Effective for short of breath, rating 1-4, (mean ± SD)
       Effective for cough, rating 1-4, (mean ± SD)
       Effective for wheezing, rating 1-4, (mean ± SD)
       Emergency treatment, frequency previous year (%)
Lung function
        PEF % predicted (mean ± SD)
        FEV1/FVC (mean ± SD)
18.1 ± 15.9
75.0
100
2.1 ± 1.0
2.0 ± 0.8 
1.8 ± 1.5
87.5
25.0
87.5
50.0
12.5
25.0
2.0 ± 0.0
2.1 ± 0.4
1.9 ± 0.6
12.5%
99.3 ± 16.8
0.82 ± 0.11
17.0 ± 15.4
75.0
100
1.5 ± 1.0
1.5 ± 1.0
1.0 ± 1.4
50.0
50.0
100.0
50.0
50.0
0.0
2.0 ± 0.0
3.0 ± 1.4
2.7 ± 1.2
50%
103.1 ± 18.7
0.62 ± 0.18
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Table 2. Manipulation success and treatment outcome variables among patients in immediate 
treatment (n=8) and waiting list (n=4) conditions
Pre-
Treatment
Post-Treatment§ Follow-up§ Time effect for 
df=2,14$
Effect
size d
End-tidal pCO2
        Treatment
        Waiting-list
34.4 ± 4.3
35.9 ± 4.2 
38.5 ± 5.8*
35.3 ± 3.9
40.3 ± 2.6** F=8.71, p=.011 1.83
Respiration Rate
        Treatment
        Waiting-list
15.1 ± 3.9
16.3 ± 4.1
10.0 ± 3.6*
16.4 ± 3.4
8.9 ± 4.9** F=6.79, p=.030 0.81
Asthma Symptoms
        Treatment
        Waiting-list
1.3 ± 0.5
0.6 ± 0.4
0.8 ± 0.5**
0.6 ± 0.5
0.4 ± 0.3** F=14.03, p<.001 1.29
Asthma Symptom (Distress)
        Treatment
        Waiting-list+
1.1 ± 0.6
0.6 ± 0.3
0.6 ± 0.7**
0.9 ± 0.4
0.5 ± 0.5** F=7.34, p=.007 0.89
Asthma Control#
        Treatment
        Waiting-list
1.3 ± 0.9
0.8 ± 0.8
1.0 ± 0.8
0.9 ± 0.8
0.5 ± 0.4* F=5.45, p=.021 1.01
FEV1
        Treatment
        Waiting-list
2.33 ± 0.47
2.24 ± 0.73
2.32 ± 0.33
2.53 ± 0.42
2.36 ± 0.46 F=0.05, p=.857 0.07
Rint
        Treatment++
        Waiting-list+
0.49 ± 0.18
0.42 ± 0.20
0.44 ± 0.10
0.42 ± 0.17
0.39 ± 0.10 F =1.53, p=.257 0.51
PEF Variability (%)
        Treatment
        Waiting-list
25.5 ± 15.4
17.6 ± 14.8
19.8 ± 12.2*
22.0 ± 20.3
18.2 ± 11.4* F =4.41, p=.035 0.78
§ significant difference from pre-treatment values: * p<.05, **p<.01
$ Time effect for treatment group (n = 8) only
#Scoring direction: lower values equals higher control
+ n = 3    ++ n=7Figure Legends
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Figure 1.  End-tidal pCO2 (a) and respiration rate (b) across pre-treatment, post-treatment, 
and follow-up measurements in 8 asthma patients participating in pCO2-biofeedback assisted 
breathing training
Figure 2.  Treatment outcome in asthma symptoms (a) and PEF variability (b) for 8 asthma 
patients participating in pCO2-biofeedback assisted breathing training
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Figure 1 a,b
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Figure 2 a,b
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